Consonance, Jay Mohr partner to invest in deprioritized therapeutics

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners (New York, N.Y.) plans to make its first therapeutics investments out of its

Read the full 247 word article

User Sign In